Zenas BioPharma, Inc. (ZBIO)
NASDAQ: ZBIO · Real-Time Price · USD
17.81
-0.20 (-1.11%)
Apr 29, 2026, 10:29 AM EDT - Market open
Zenas BioPharma Balance Sheet
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 |
| Cash & Equivalents | 110.64 | 319.74 | 56.86 | 67.21 |
| Short-Term Investments | 232.55 | 31.02 | - | - |
| Cash & Short-Term Investments | 343.19 | 350.77 | 56.86 | 67.21 |
| Cash Growth | -2.16% | 516.93% | -15.40% | - |
| Other Receivables | 1.2 | 2 | - | - |
| Receivables | 1.2 | 2 | - | - |
| Prepaid Expenses | 6.78 | 3.07 | 1.65 | 1.24 |
| Restricted Cash | - | 0.09 | - | - |
| Other Current Assets | - | - | 1.3 | - |
| Total Current Assets | 351.17 | 355.92 | 59.8 | 68.44 |
| Property, Plant & Equipment | 1.39 | 1.19 | 1.01 | 1.8 |
| Long-Term Investments | 17.27 | - | - | - |
| Long-Term Deferred Charges | 0.71 | - | 1.39 | - |
| Other Long-Term Assets | 13.1 | 12.86 | 5.97 | 4.33 |
| Total Assets | 383.64 | 369.97 | 68.18 | 74.58 |
| Accounts Payable | 7.11 | 17.14 | 5.4 | 5.82 |
| Accrued Expenses | 54.31 | 39.16 | 17.01 | 19.44 |
| Current Portion of Leases | 1.12 | 0.79 | 0.56 | 0.72 |
| Current Income Taxes Payable | 0.12 | 0.21 | 0.3 | - |
| Total Current Liabilities | 62.65 | 57.29 | 23.26 | 25.97 |
| Long-Term Debt | - | - | 20.3 | - |
| Long-Term Leases | 0.21 | 0.22 | 0.26 | 0.81 |
| Other Long-Term Liabilities | 78.64 | - | - | - |
| Total Liabilities | 141.5 | 57.51 | 43.82 | 26.78 |
| Common Stock | 0.01 | 0 | - | 0 |
| Additional Paid-In Capital | 1,007 | 699.65 | 4.65 | 1.03 |
| Retained Earnings | -765.13 | -387.39 | -230.4 | -193.28 |
| Comprehensive Income & Other | -0.06 | 0.19 | 0.04 | -0.04 |
| Total Common Equity | 242.14 | 312.46 | -225.72 | -192.29 |
| Shareholders' Equity | 242.14 | 312.46 | 24.37 | 47.8 |
| Total Liabilities & Equity | 383.64 | 369.97 | 68.18 | 74.58 |
| Total Debt | 1.33 | 1 | 21.11 | 1.53 |
| Net Cash (Debt) | 341.87 | 349.76 | 35.74 | 65.68 |
| Net Cash Growth | -2.26% | 878.52% | -45.58% | - |
| Net Cash Per Share | 7.64 | 26.50 | 23.34 | 44.02 |
| Filing Date Shares Outstanding | 57.36 | 41.8 | 1.58 | 1.55 |
| Total Common Shares Outstanding | 54.49 | 41.79 | 1.58 | 1.55 |
| Working Capital | 288.52 | 298.63 | 36.55 | 42.48 |
| Book Value Per Share | 4.44 | 7.48 | -143.15 | -124.11 |
| Tangible Book Value | 242.14 | 312.46 | -225.72 | -192.29 |
| Tangible Book Value Per Share | 4.44 | 7.48 | -143.15 | -124.11 |
Source: S&P Capital IQ. Standard template. Financial Sources.